DGAP-News

MOLOGEN AG: Convertible bond worth EUR4.99 million successfully placed

DGAP-News: MOLOGEN AG / Key word(s): Corporate Action MOLOGEN AG: Convertible bond worth EUR4.99 million successfully placed 17.01.2017 / 15:31 The issuer is solely responsible for the content of this announcement. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Press Release N 2 / 2017 of 01/17/2017 MOLOGEN AG: Convertible bond worth EUR4.99 million successfully placed

- Total amount issued: EUR4.99 million, maturity of 8 years

- Coupon of 6% p.a.

- Major shareholder GTD exercises its subscription rights in full and additionally subscribes all bonds not taken up by other shareholders

Berlin, 17 January 2017 - Biotechnology Company MOLOGEN AG (ISIN DE0006637200, SIN 663720) today announced the full placement of a convertible bond with a total amount of EUR4.99 million. The bonds to be issued in a denomination of EUR10.00 each with a maturity of 8 years feature 6% interest p.a. In the period from 1 April 2017 up to maturity, it will be possible to convert the bonds into a maximum of 3,124,994 shares in the company in total at a conversion price of EUR1.60 per share.

The convertible bond was issued as part of a prospectus-exempt public rights offering. Almost 60% were subscribed by existing MOLOGEN shareholders. Global Derivate Trading GmbH (GDT), the major shareholder of the company, took up all convertible bonds 2017/2025 that were not subscribed. Ahead of the transaction, GDT made a binding commitment to the company that it would purchase 60% of convertible bonds 2017/2025. Overall, the order book reflected a significant demand overhang.

Issuance and delivery of the bonds will take place on 20 January 2017. The funds inflow is to be used for the ongoing implementation of the "Next Level" strategy program and specifically the further development of the lead product, immunotherapy with lefitolimod. Furthermore, the additional funds inflow will give the company greater financial scope for implementing and securing other strategic and operating measures in 2017. In addition, this puts the company in a stronger position for potential future negotiations on partnership and licensing agreements. Based on today's planning, financing is expected to be secured until the start of 2018.